Preclinical evaluation of 89Zr/177Lu-labelled anti-B7-H3 monoclonal antibody for theranostics in B7-H3-positive liver cancer
Labelling B7-H3mab with <sup>89</sup>Zr enabled non-invasive assessment of B7-H3 expression, while <sup>177</sup>Lu labelling effectively suppressed tumour growth in B7-H3-positive liver cancer. Further clinical evaluation of this B7-H3-targeted diagnostic and therapeutic agent may be of significant importance for patients with liver cancer.
Authors
- Lü Zhou (ORCID: https://orcid.org/0000-0001-9014-6350)
- Mingsong Shi (ORCID: https://orcid.org/0000-0002-8979-5844)
- Rui Luo (ORCID: https://orcid.org/0000-0001-5280-0999)
- Yan Zhou (ORCID: https://orcid.org/0000-0002-5547-2668)
- Xiaoan Li (ORCID: https://orcid.org/0000-0003-1916-311X)
- Tao Wu (ORCID: https://orcid.org/0000-0003-2477-8004)
- Yuanyuan Liang (ORCID: https://orcid.org/0000-0003-0360-286X)
- Zhengguo Chen (ORCID: https://orcid.org/0000-0002-0607-0347)
- Xia Yang
Institutions
- University of Electronic Science and Technology of China (CN)
- Sirim Berhad (MY)
- China Academy of Engineering Physics (CN)
- Mianyang Central Hospital (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1016/j.ejps.2025.107371
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36